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INTRODUCTION 
During the past 33 years. orthotopic liver transplantation 
has become a highly successful form of therapy, and as of 
this writing it is being performed at more than 100 
institutions in the U.s., with a similar number in Europe. 
This is testimony to the great advances achieved in this field 
since the 1960s. when there were essentially only two teams 
actively engaged in liver transplantation, one at the 
University of Colorado and the other at Cambridge 
University (England), Essential to its success has been the 
work in the laboratory. where the surgical technique and all 
the refinements of this operation, as well as a panoply of 
relevant physiologic concepts, were developed before being 
introduced in the clinical arena. 
The laboratory work also allowed many surgeons around 
the world to practice, in order to be able to do liver 
transplantation safely. This is still perhaps the most 
complex operation in routine use today, and good 
technique is crucial to a satisfactory outcome. A fall-back 
system such as that for kidney, heart, pancreas, and 
intestinal transplantation (i.e. dialysis, ventricular assist 
device. insulin. and parenteral hyperalimentationl does not 
exist for the liver. Thus. the smallest mistake in the surgical 
management of the patient may prove fatal. 
In this chapter we will describe how liver transplantation 
came to be a clinical discipline. We also will consider its 
future developments, including drug-free graft acceptance 
(based on the "2-way paradigm") and the prospects of 
clinical xenotransplantation. 
THE LABORATORY-CLINIC INTERFACE 
Experimental work in the laboratory has been critical to 
each major step in the evolution of liver transplantation. 
Evidence obtained in the animal models has been 
transferred to the clinics, and conversely. problems 
encountered in the patients have been brought back to the 
animal laboratory for clarification (1), as had been done 
earlier for kidney transplantation (2). This flux has been 
continuous for almost 40 years. It resulted in the 
development of operative techniques. the improvement of 
immunosuppression. and clarification of previously 
enigmatic physiologic principles. The objective was to 
avoid human experimentation. rather than depending on 
it, when the time came to apply this potentially life-saving 
procedure in the clinic. The first attempt to replace a 
human liver was preceded by more than 7 years of animal 
experiments involving hundreds of animals (3). 
A co-product of these efforts was the concept of team 
construction in the laboratory. The more experience gained 
in the laboratory, the better the team will perform in the 
human operating room. In addition, a clinical liver 
transplant demands the strict cooperation among 
specialists in different fields including health care 
administration. The recipient candidate is evaluated by 
surgeons, hepatologists, anesthesiologists. radiologists, 
psychiatrists/psychologists. nurses, social workers. and 
many other care providers. The actual operation requires 
separate donor and recipient teams, the activities of which 
must be closely knit. During the transplant operation, 
cooperation among surgeons. anesthesiologists, 
perfusionists, and nurses is essential. From the very 
beginning, one of the objectives of laboratory work was to 
create harmony amongst the specialists and also those with 
whom the team would react. 
The core roles of the surgeons and the steps involved in 
the operation are identical to those of everyday clinical 
practice. However. the operation and postoperative care 
are more complex. We have stated earlier: "It is unlikely 
that anyone would attempt clinical liver transplantation 
without first personally recapitulating in the laboratory at 
least some of the earlier experiments in dogs or alternatively 
in pigs" (4). Someone inevitably will emerge from this 
experience as the team leader. most commonly but not 
necessarily a surgeon. Rigidity, impatience. selfishness, 
dishonesty, inhumanity, ignorance. and poor organizational 
skills are disqualifying characteristics. In addition to 
possessing these graces. as well as professional competence, 
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the leader must hm-e those scientific instincts which allow 
advances. 
There are two different approaches to transplantation of 
the liver. \'\!ith one method an allxiliar~D graft is inserted 
heterotopicalh' at a non-anatomical site. withollt removal of 
the native liver. The other is to transplant the graft 
orthotopically (in its natural location). after removal of the 
recipient liver (total hepatectomy I. 
Auxiliary' Lil'er Tra1lsplalltatioll 
The first report of liver transplantation appeared in the 
scientific literature in 1955 when C. Stuart Welch of Albam 
(New York), described the insertion of an auxiliary canine 
liver into the right paravertebral gutter or pelvis -of non-
immunosuppressed dogs (Figure 1.1) (5). The liver arterial 
supply was derived either from the aorta or the iliac artery. 
The allograft portal vein was revascularized by rerouting 
high volume systemic venous flo\\' into the transplanted 
Donor 
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-- Hepatic a. 
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crK~ure 1. ] - Auxiliary li\'er transplantation in J dog bv J modificarion at' 
\,\'elch's original rechnique. :\ore rhar rhe reconsritured porral blood 
supply is from rhe disral mtenor vena Ca\'Cl. (From: ~!grzl TE. et a!. 
Immunosuppression afrer experimenral and clinical homorransplanrarion 
ot the liver. Ann Surg 196-l:160:-l11--l3L), Used bv permIssion!. 
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liver's portal system. This was done b\· end-w-end 
anastomosis of the host iliac \'ein or inferior vena G\\'a W 
the portal \'ein of the allograft (Figure 1.1), The graft 
outHow was directed into the host systemic \'enous system 
by an end-to-end anastomosis between the supmhepatic 
inferior \'ena cava of the graft and the inferior vena cava (or 
common iliac vein) of the host. The "blind" distal stump 
of the graft inferior vena cava was ligated. and the bilian' 
tract reconstruction was performed by :l cholecysto-
duodenostomy (Figure 1.1). 
The livers transplanted with this technique into non-
immunosuppressed dogs produced bile for several days 
and then ceased to function. When grafts underwent 
astonishingly rapid atrophy, the shrinkage was considered 
at first to be one of the manifestations of unmodified 
rejection (5.61. The misconception was not corrected until 
the early 1960s, when Welch's experiments were repeated 
in mongrel dogs immunosuppressed with azathioprine. the 
drug whose laboratory testing in a canine renal transplant 
model had been spearheaded by CaIne (7, 8), Although 
protection of the auxiliary hepatic allografts was unreliable, 
it was good enough in many experiments to completely 
prevent cellular rejection for 7 to 30 davs, Yet, the livers 
had profound atrophy by the end of the first week (9) 
(Figure 1.21. The conclusion from these observations was 
some constituends) of the splanchnic venous blood (either 
a hormone [suspected to be insulin] or nutrients) that was 
present in high concentration in normal portal. but not 
systemic, blood had liver supporting qualities (9), Efficient 
removal of this "hepatotrophic" substance(s) by the first 
pass through the native liver apparently made it unavailable 
to the graft. This hypothesis was strengthened bv the 
demonstration that the auxiliarv livers had a nor~al or 
supernormal volume of flow (io). The shrunken porta-
prival liver had characteristics that were indistinguishable 
from an Eck fistula liver. 
The RippLe Effect - The importance of this discoverv was 
recognized immediately. Until these experiments 'were 
performed under immunosuppression, an entrenched 
dogma of hepatic physiology had been that the volume, not 
the source, of portal venous blood flow was the critical 
factor in hepatic homeostasis (the flow hypothesis [11, 12]). 
Now. overthrow of the flow hypothesis had begun (13, 14). 
Fifteen more years were required, however, for its 
completion. culminating in the demonstration that insulin 
was the principal splanchnic hepatotrophic factor ( 15 -19), 
Eventualh-. the identification of a familv of factors with 
insulin-like hepatotrophic properties th;t controlled liver 
structure. function, and the capacity for rei!eneration 
defined the new field of hepatotrophic physiology (20, 21l. 
These developments were made possible by recognition 
of the double li\'er principle wherebv one liver dominates 
the other bv its a\'id clearance of hepatotrophic factors (9) 
(Figure 1.3Al. The consequent pervasive impact on the 
study of !i\'er physiology in general and upon the ill vivo 
I 
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ffK~/lrc /. 2 - The auxiliary allo!!rafr Irii!ht) and th(: 
(l'C1pient dOi!'s m\'n liver lIeft) -15 oavs after the 
l"'11Crimental transplantation W:IS performed in 
1'1(,-1. Immunosuppression wus with azathioprine. 
ano th(:re was no hislOpatholo!!ieal evidence of 
relection. Note the well-preserved but dimensio-
rd]\' n:duced general struetur(: 01 the allograh. 
lh~ i!ullblaoder did not shrink proportionately. 
I From: Starzl TE. et al. Immunosuppression after 
nl'erimcntul and clinical homotransplantation of 
the li,·cr. Ann Surg 196-1:160:-111--139. Used by 
I'l'fmission I. 
study of hepatic growth factors in particular was slow to 
evolve. After the primary discovery, a series of non-
transplant models was developed (13-19), in which the 
animal's own liver was divided into competing fragments 
(Figure 1.3B-Dl. With these models and particularly the 
final one shown in Figure 103 D, 8 growth factors with 
potent hepatotrophic effects (18-30) as well as 2 with the 
opposite action (29, 30) were identified (Table 1l. 
The first clearly delineated hepatotrophic factor was 
insulin, (18, 19) followed 4 years later (22) by the cytosol 
of hyperplastic liver cells containing the" augmenter of liver 
regeneration" (ALR) , a molecule originally called hepatic 
stimulatory substance (HSSl. When infused by itself into 
the defunctionalized hilar portal vein after portacaval 
shunt. each of the 8 substances could prevent the 
hepatocyte and whole organ shrinkage caused by the Eck 
fistula. In addition. they augmented the hyperplasia 
characteristic of the Eck fistula liver with a response similar 
to but more sustained than the regeneration response 
following a moderate partial hepatectomy. The develo-
pment of the in vivo Eck fistula assay (Figure 103D) was 
critical for the study of liver growth control. Because only 
2 of the 8 hepatotrophic factors (transforming growth 
factor-alpha [TGF-a] and hepatocyte growth factor 
[HGFJl stimulate mitoses in tissue culture, the other 6 
could not be identified as grO\\'th factors with ill vitro 
techniques. 
The most elusive of the 6 non-mitogenic "occult .. growth 
factors was the .. intrinsic hepatic growth factor", ALR 
which is present in the hyperplastic livers of weanling rats 
or in the residual liver fragment of adult animals of several 
o 
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FIgure 1.3 - Growth factor detection with coexisting liver and Eck fistula 
models alone or in combination: (.-\ I auxiliarv liver transplantation: (B) 
pamal portaca"al transposition: ICi splanchnic venous division: (0) Eck 
tistula plus selective infusion of tested substance. IFrom: Francavilla A. 
ct ;II. Augmenter ot liver regenemtion: its place in the uni\'erse of hepatic 
growth tactors, Hepawlog" 199-1:2(li31:i-li-i5i. Used by permission!. 
TABLE 1 
GRo\X'TH FACTORS REVEALED BY STUDIES 
IN bC~ FISTULA MODELS (199-ti 
Stimulatory 
Hormones: 
Insulin 
(; ro\\'th Factors: 
Cytosol substrate and ALR 
IGF II 
TGF-a<l 
HGP 
Immunosuppressants: 
Cvclosporine 
FK506 
Immunophilins: 
FKBP12 
Inhibitory 
Growth factors: 
TGFJlb 
Immunosuppressant: 
Rapamycinb 
"Mitogenic in tissue culture 
blnhibitory in tissue culture 
1\('/1'1'1'11("(' So. 
18. 19 
21. 22.23. 2-t 
25 
25 
25 
26 
27 
28 
29 
30 
species following partial hepatectomy. Its purification to 
>800,000 (23, 31, 32) and cloning (24) after 16 years of 
effort in our laboratories added another important 
component to the complex network of modulators, both 
stimulatory and suppressive, which regulate hepatocyte 
proliferation and hepatic regeneration at the organ leveL In 
these days of cellular and molecular biology, it is striking 
that the 2 operations of portacaval shunt (Eck's fistula) (33) 
and auxiliary liver transplantation (5) described in dogs 78 
years apart played an indispensable role in this 
development_ 
The new growth factor ALR is a unique heat stable 
peptide whose gene exhibits a 50% homology with the dual 
function nuclear yeast gene ERVI (3-11. The ERV1 gene is 
required for oxidative phosphorylation (respiratory chain) 
and also is essential for mitosis, which ceases in 3 --I days 
following gene deletion in the veast, RaccharomDsc~s 
cerevlsiae. If, as we suspect, Ai1~ is the mamm~lian 
homologue of ERVl, it is apt to be a major growth 
regulatory gene. Subsequent to the discovery of the rat ALR 
gene. we have identified the mouse and human ALR genes 
(and the protein products) (35), These were all found in all 
species to be highly conserved and preferentiallv expressed 
U\TR qoy:--;~miy:--;qKyqfE 1:--' 
in the testis and the liver (2-1, 351. The ALR gene maps to 
the mouse chromosome 17. in a region syntenic with 
human chromosome 16. where the allele-rich Tit region 
involved in spermatogenesis is located. The ALR protein 
appears to be a protein with important potential 
physiologic properties. not exclusively limited to liver 
regeneration. but rather with roles that are involved in the 
synthesis or stability of the nuclear and mitochondrial 
transcripts that are present in actively regenerating cells. 
and particularly the germ cells of the testis. 
The Practical ApplzcatiollJ - Although auxiliary liver 
transplantation was envisioned by Welch as a potential 
treatment for liver cirrhosis or other non-neoplastic 
diseases, the laboratory experiments showed at the 
beginning that the procedure had a fundamental design 
defect. The immediate impact of its laboratory investigation 
(6) was prevention of a tragedy in which unwise clinical 
trials of the Welch operation might have been undertaken. 
as appeared originally to be logicaL The liver is an unpaired 
organ. Instead of removing and replacing it, why not 
transplant a second (auxiliary) liver in some convenient 
location in the abdomen? Implantation of an auxiliary liver 
had a special appeal for teams already involved in kidney 
transplantation. Kidney grafts are essentially never placed 
in a normal anatomic location and frequently they are 
implanted without removing the 2 native kidneys. It was 
easy to envision how an extra liver could go in the same 
general location. This was, in fact, Welch's original 
intention. 
The first discoveries of the hepatotrophic effect of 
splanchnic venous blood pushed the pendulum of the early 
1960s toward the seemingly more difficult operation of 
liver replacement, Here also, the necessity was apparent for 
assuring portal venous inflow from the effluent blood of the 
other visceral organs. The same principle applies today. If 
orthotopic liver transplantation is to be performed in 
patients who have portal-systemic shunts, the shunts 
should be disconnected. In patients who have thrombosis 
or damage to their own portal veins, extension or jump 
grafts should be used to ensure delivery to the liver of the 
hormone and nutrient-rich splanchnic' venous blood (37· 
40). 
Finally, it was possible at long last to understand what 
caused the manifestations of Eck's fistula in animals and in 
humans subjected to portacaval shunt. The reason was that 
portal systemic shunt procedures placed the liver in a 
variably insulinoprival state (18, 19, 41l. In 1961. Bollman. 
the world's leading authority on the subject, wrote: "In the 
83 years since it was first reported. the Eck fistula has been 
reasonably successful in hiding its secrets as well as giving 
rise to many additional questions fundamental to an 
understanding of the functions of the intestine. liver. and 
brain." (-l21. The hepatotrophic field that gre\\' from the 
earliest efforts to evaluate the potential clinical value of 
auxiliary liver transplantation blew away the fog. 
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(.'(mi"e Ortbotopic Lil'er Tratlspla"tatio" 
The concept of liver replacement first appeared in the 
literature in 1956 in a one page notation .1 ack Cannon of 
tht: Universitv of California. Los Angeles. entitled "Brief 
]{eport" (431.'ln it. he indicated that he had attempted the 
llpcration in dogs. apparently after reading WeIch's article. 
(:annon suggested that the liver, by virtue of its possible 
role in the still poorly understood immune system. might 
not contribute to its own rejection. No technical 
information or results were given except for the statement 
that "several successful operations" had been performed ... 
"without any survival" (4 3), Frustration in accomplishing 
operative survival also was encountered at the first 2 
research programs that made this a formal objective. 
These were begun independently in the summer of 1958 
in Boston at the Peter Bent Brigham Hospital (Harvard) 
144-46). and in Chicago at Northwestern University (47, 
.J81. Because there was no way to prevent or control 
rejection, maximum survival was 12 and 20.5 days in the 2 
laboratories, respectively. By the time of the April 1960 
meeting of the American Surgical Association (49), 31 of 
these procedures had been done in Boston and 80 in 
Chicago. Rejection was always present after 5 or 6 days in 
both series, and generally it was the principal cause of 
death. The principles that emerged from this collective 
experience were: 1) the need for splanchnic venous blood 
for optimal portal revascularization (see preceding section), 
2) core cooling of the allograft by infusion of chilled 
solutions into the portal vein as is practiced clinically today, 
and 3) decompression of the occluded splanchnic and 
systemic venous pools into the upper vena caval system 
through external venous bypasses during the anhepatic 
stage. 
In addition to liver transplantation alone, modifications 
had been added by the end of 1959, including the 
multivisceral engraftment procedures (50, 51) that would 
be used clinically with essentially no change 3 decades later 
(52), The interrelationship of all abdominal viscera 
transplant operations (53) was already apparent by the early 
1960s (Figure 1.4). 
LIVER PRESERVATION 
~lDpotbermia 
The efforts in 1958-1959 to preserve dog livers came only 
a short time after the preservative value of cooling per se 
was described. While studying total body hypothermia for 
cardiac surgery in the 1950s. Owens. Prevedal. and Swan 
(54) observed that lower temperatures protected the 
kidnevs and other abdominal organs from the injury of 
cross-clamping of the thoracic aorta. This effect of renal 
cooling was promptly confirmed in simpler ischemia 
~--l~ W/', " g~I"D--"- ~ / \ .. ' 
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Figure 1.4 - The intra-abdominal viscera (center) that constitute a 
multivisceral graft (50. 51), In the periphery as shown, the liver, intestinal, 
and pancreas grafts that are part of this complex and can be transplanted 
alone or in various combinations (53). (From: Starzl TE. The 
contribution of transplantation to gastroenterologic knowled/2e. In: The 
Growth of Gastroenterolo/2ic Knowled/2e during the 20th Century, JB 
Kirsner [Ed.]. Lea and Febi/2er. Philadelphia. Pennsylvania. 1994. pp. 
348-369. Used by permission). 
models (55), When Lillehei and his associates began 
attempts at bowel autotransplantation and allotransplan-
tation in 1958, they cooled the intestine by immersing it in 
cold electrolyte solution (56). Refrigeration through the 
thin-walled bowel was rapid, an advantage that did not 
pertain to solid organs . 
Core Cooling 
It was recognized during the canine liver transplant 
experiments of 1958-1959 that core cooling of the organ to 
be removed was an essential component of any 
procurement procedure. After this was applied to 
experimental liver transplantation (47), the concept of core 
cooling was promptly extrapolated to human kidney 
transplantation (57). It remains today the single most 
important step in any organ procurement technique. The 
easiest way to avoid warm ischemia is by in situ infusion of 
----_ ....... - --------
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the preservation solution. chilled to 4°C. at the time. of the 
circulatorv arrest. The remainin~ technical aspects at organ 
retrieval. ;nd the refinements added in the following years. 
are secondarv to this critical maneuver (58), 
The Slush Techniquer - The first solution used was chilled 
lactate Ringer's solution. replaced in the late 1960s by the 
so-called Collins solution. which has an electrolyte 
composition close to the intracellular one (59), This 
solution was successfully used for about 20 years, until the 
introduction of the Universitv of Wisconsin solution (60, 
61), which significantly exte~ded the duration of organ 
viabilitv. In 1975 and 1976, Benichou et al (62) in Denver 
and W;ll et al (63) in Cambridge showed that with Collin's 
solution and with a plasma-like solution, respectively, dog 
livers could be cold-stored for 12 hours or more. Now, it 
became possible to ship livers from city to city, but within 
a safe time limit of onlv about 6 hours. After Tamieson et 
al (64) demonstrated that canine livers could be preserved 
reliablv for 24 hours with solution at the University of 
tisco~sinI the promise of expanded organ-sharing 
between regions and countries, or even trans-Atlantically, 
became practical and commonplace. 
Multiple Organ Procurement - In the early days of 
multiple organ procurement, the individual organs were 
skeletonized. After all of the dissection was completed, the 
kidneys were removed and cold perfused on the back table. 
The liver and heart then were removed simultaneously. 
However, the removal of all four organs was a rare event. 
The first time the kidneys, liver, and heart were removed 
from a single donor was on 17 April, 1978 during a visit by 
the University of Colorado team to the University of 
Minnesota. It quickly became obvious that in situ cooling 
of organs was going to be necessary if extrarenal organ 
transplantation were to flourish. During the times when the 
numbers of liver or heart transplants were small, the 
annoyance caused for renal transplant surgeons by 
multiple-organ procurement was relatively minor. As 
demand for extrarenal organs increased, a "civil war" 
loomed between those solely interested in the kidney, and 
the gastrointestinal and thoracic surgeons. 
Consequently, a major educational effort was required to 
unite these diverse groups with a common plan. The 
procedures developed in Denver and Pittsburgh were 
demonstrated throughout the eastern two-thirds of the 
United States and Canada, and at the request of the 
Surgeon General of the United States (Dr. C.E. Koop). a 
description of the new operation of multiple-organ 
procurement was published (58), This was followed by 
modifications for unstable donors or even for donors whose 
hearts have ceased to beat (65). In the space of less than 
five vears, these standardized multiple-organ procurement 
tech~iques were being used interchangeably, not only from 
city to city but from country to country throughout the 
world. 
U\'ER TR:\i\SPL:\i\T:\TIOi\ 
Continuous Per:fusio1l 
The alternative to infusion and cold storage is continuous 
perfusion. In a prototype of many later efforts. whole body 
or regional cadaveric perfusion was developed in dogs (66) 
and in humans (67. 68) using a pump oxygenator into 
which a heat exchanger was incorporated for cooling. 
Subsequently, ex vivo perfusion of dog livers for 24 hours 
was shown to be feasible bv Brettschneider et al (69) using 
whole blood and a simpl~ oxgenerator that wa!? housed 
along with the grafts within a hyperbaric oxygen chamber 
as described earlier for kidneys bv Ackerman and Barnard 
(70), Although several huma~ li~ers were preserved with 
this method, the complexity of the approach and the 
potential dangers of the high compression oxygen chamber 
caused the technique to be abandoned. Nevertheless, the 
concept of continuous ex vivo organ preservation has never 
lost its appeal, because it is widely thought that only this 
technology will permit true organ banking. 
VENOVENOUS BYPASS 
In the dog, survival after liver replacement is not possible 
without shunting the venous return from the occluded 
splanchnic and inferior vena cava vascular beds to the 
superior vena cava during the anhepatic phase (45, 47). 
This early observation provided the foundation for the later 
development of the venovenous bypass used nowadays in 
clinical practice. However, venovenous bypasses were not 
used systematically for orthotopic liver transplantation in 
humans until 1983 (71). The result was that liver 
transplantation repetitively was performed in patients 
under conditions that limited its usefulness. increased its 
perioperative risk and made training of the next generation 
of hepatic surgeons difficult. The mistake was made of 
believing that the fundamental bypass principle delineated 
in animals was not relevant in humans. 
A Recycling of History 
How this error was rectified cannot be traced easily from 
the articles describing the steps, The stimulus for 
reassessment was a persistent 5 -1 0 % intraoperative 
mortalitv that was due almost entirely to poor patient 
toleranc~ during the venous occlusions of· the anhepatic 
phase. However, nothing decisive was done to remedy the 
situation until a tragedy occurred in Pittsburgh on 13 May, 
1982 that utterly demoralized the transplant team. A 
teenage hemophiliac male with chronic active hepatitis died 
on the operating table from the combination of bleeding. 
third space Huid sequestration and cardiovascular 
instabilitv that was then common during hepatectomy and 
the sewi~g-in of the new liver. 
The emotional burden caused by the death of this 
1 
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popular patient \\'as not lightened by the thought that we 
might have been hardened bv our own repeated failures to 
the point of no longer making improvements. The program 
was closed until 15 .1 une. 1982 when one of us (TES) 
n:quested Dr. Henry T. Bahnson. Chairman of the 
Department of Surgery at the University of Pittsburgh. to 
devise a pump-driven bypass for a liver replacement 
scheduled for that evening. Bahnson grasped the essence of 
the problem instinctively. and agreed immediately. That 
night, liver transplantation was carried out under 
venovenous bypass in a 6-year-old child with biliary atresia. 
The bypass was performed under 3 mg/kg heparin with a 
roller pump and other conventional equipment used for 
open-heart surgery. This technique of a pump-driven 
bypass had been described in dogs 10 years earlier by 
Cutropia et al (72), but their article was unknown to us at 
the time. There was little trouble in reversing the heparin 
effect afterwards. All those who were there that night 
(including Luigi Fassati of Milan) were ecstatic about the 
ease and non-stressful nature of the transplantation under 
bypass conditions. 
By 1 July, 1982 abstracts describing the technique were 
submitted to the Southern Surgical Association and to the 
American Association for the Studv of Liver Diseases. Both 
were rejected. In the meanwhiie, problems had been 
encountered with reversal of the heparin effect in several 
of the adult recipients. Venovenous bypass under systemic 
heparinization had worked marvelously in those patients 
with relatively "simple" diseases such as primary biliary 
cirrhosis and in recipients who had never had any previous 
operations. The same was not true in patients with difficult 
pathology or exceptionally advanced disease and especially 
in those who had undergone multiple procedures 
previously. Here, the bleeding from the raw surfaces was so 
great and the heparin effect was reversed with such 
difficulty that the value of bypass technique was vitiated. 
Two patients died of hemorrhage when clotting could not 
be restored. 
The Heparin-Free Bypass 
From a lifetime of experience with cardiopulmonary bypass 
techniques, Bahnson was convinced that eliminating the 
systemic heparinization would not be safe. However, two 
of Bahnson's young associates. Dr. Bartley Griffith and Dr. 
Robert Hardesty, had avoided systemic heparinization in 
patients with pulmonary insufficiency who had been 
supported with extracorporeal membrane oxygenators 
perfused \dth an atraumatic centrifugal pump. The rest of 
their equipment. including the cannulas and tubing, was 
not much different than in the first trials under heparin. In 
September. 1982, they proposed the use of venovenous 
bypass without heparin. 
On 30 September. 1982. work began on dogs in the 
laboratory. The project was assigned to Dr. Scot Denmark. 
the resident on cardiac surgical research rotation. Griffith 
and Denmark provided the bvpass equipment. The liver 
transplantations were performed by members of the 
transplantation service including the senior fell o\\'. Dr. 
Byers Shaw. J L By the end of 1982. the preclinical 
prepa~ation reported by Denmark at the Surgical Forum of 
the American College of Surgeons in October, 1983 already 
had been completed (73), However, clinical trials of the 
non-heparin bypass were not started, in part because it was 
difficult to predict which patients really needed it. In 
addition, there still was uneasiness about the possibility of 
clot formation in bypass tubing and consequent pulmonary 
emboli. Finally. Shaw (by now a junior faculty member), 
who later became an enthusiastic proponent of the 
technique (74), was initially opposed to its use. 
During the Christmas season of 1982 and in January of 
1983, three more deaths occurred on the operating table in 
much the same way as with the earlier hemophiliac patient. 
As a consequence, a command decision was made that 
venovenous bypasses must be used henceforth for all adult 
recipients of liver transplants. In view of Bahnson's 
previous trepidation about using non-heparin bypass, 
Griffith, as an additional precaution, added the heparin-
bonded (Gott) cannulas for both the outflow and inflow 
limbs of the system (75); even though this was not an 
integral part of the animal technique. The problems with 
bleeding that had been aggravated by systemic 
heparinization were greatly ameliorated. It was obvious 
that from that moment onward liver transplantation could 
be a far more reasonable procedure that would be within 
the capability of many general and vascular surgeons and 
which henceforth could be taught to surgeons in training 
in a systematic way. 
The sequence of articles from this laboratory-generated 
advance was orderly, but the actual publication schedule 
was not. The rejection of Bahnson's two abstracts expunged 
the beginning of these events from the record with the 
exception of a brief notation in a 1982 review article (71). 
The animal work on non-heparin bypasses by Denmark 
(73) appeared promptly in the literature. However, the 
descriptions by Griffith et al (75) of the first clinical 
application of the new method (Figure 1.5) as well as details 
of technique were delayed. These were sent to Surgery, 
Gynecology & Obstetrics in July, 1983, but the article was 
not published until more than 1-112 years later (75). In the 
meantime. an account of the advantages of venovenous 
bypasses in liver transplant recipients was given by Shaw at 
the American Surgical Association in the spring of 1984 
and published the following October in Annals 0/ Surgery 
(74), 
Such priority questions were unimportant. However, 
noteworthy was Bahnson's encouragement of Griffith to 
pursue an idea in the laboratory that he, Griffith's Chief. 
initially did not believe to be sound. After this, movement 
to the clinic was inexorable. 
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Are Venovenous Bypasses Necessary? 
Although not all liver transplant surgeons use venovenous 
bypasses routinely, the practicality of liver transplantation 
with venovenous bypass is so much greater compared to 
that in previous times that the principle of venovenous 
bypass, at least in selected cases, is widely accepted. 
Some surgeons use a test period of portal and venacaval 
cross-clamping before making a decision about the use of 
bypass. The development of hypotension and/or low 
cardiac output is a warning that the bypass is needed. In 
infants or very small children, the difficulty of achieving an 
effective bypass may preclude its use. For these cases, the 
piggy-back operation has a special appeal (see later). 
Ironically, severe liver disease may reduce the need for 
venovenous bypass. Picache et al (76) showed that even 
canine liver replacement, which cannot be done reliably in 
normal animals without bypass, is relatively safe when 
venous collateralization is stimulated by ligation several 
weeks in advance of the recipient's common bile duct. 
REFINEMENTS OF SURGICAL TECHNIQUE 
In principle, liver transplantation is exceptionally 
straightforward, involving the removal of the diseased 
native liver and its replacement with the liver of a cadaveric 
donor in as anatomically a normal way as possible (Figure 
1.6), All of the essential steps were described in the first 
clinical report (77), including a new technique for 
intraluminal suturing of vessels that had to be 
reconstructed without redundancy in close quarters. More 
000 1rrn~~ 00 
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Figure 1.5 - Veno venous by·pass used during the 
anhepatic stage of liver transplantation. (From: 
Starzl TE. History of the liver and other 
splanchnic organ transplantation. In: Transplan· 
tation of the Liver, Busuttil Rand Klintmalm G 
rEds.), WB Saunders. Philadelphia, Pennsylvania, 
1996. Used by permission). 
complete details of the operation were summarized in a 
1969 text (78). The operation used by Calne was essentially 
the same (79). However, technical difficulties continued for 
years. 
Figure 1.6 - Completed onhotopic liver transplantation (liver replace· 
ment J. Biliary tract reconstruction is usually with choledochojejunostomy 
(to a Roux limb) or (inset) with a choledochocholedochostomy, which is 
stented with a T tube. (From: Starzl TE. et al. Liver transplantation: a 
31-year perspective. Pan I. Curr Probl Surg 1990; XXVII(2):49·116. 
Used by permissionJ. 
._--_.- .. -----------
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Recipient Hepatectom.J' 
Performing a total hepatectomy in a patient with cirrhosis 
and severe portal hypertension is a stressful experience. In 
the early trials of liver transplantation, both donor and 
recipient procedures usually were done by the same team. 
This required a marathon effort. Today, recipient 
operations usually have a seasoned surgeon plus two or 
three assistants who are familiar with the procedure. 
Sometimes the presence of adhesions from previous 
surgery makes the standard technique of total hepatectomy 
unsuitable. If the hilum cannot be directly approached the 
suprahepatic vena cava should be isolated first, and the 
liver mobilized from cephalad to caudad approaching the 
hilum posteriorly, where it is usually relatively free of 
adhesions. 
Another useful technique is hepatectomy with preserva-
tion of the inferior vena cava. This method, called the 
piggyback operation, which was first reported by Calne 
(79) and popularized by Tzakis (80), is based on the total 
one-stage canine hepatectomy that was described in 1959 
(81) (Figure 1.7). This technique cannot be used in liver 
malignancies, where the resection margins should be as 
wide as possible. However, it has special value if a liver 
Figure 1.7 - Operative field after completion of total canine hepatectomy 
with preservation of the inferior vena cava. This experimental procedure. 
published 38 years ago (8Il. is the basis of the "piggyback" variation of 
orthotopic liver transplantation used clinically today. (From: Starzl TE. 
et al. A new method for one-stage hepatectomy in dogs. Surgery 
1959:46:880-886. Used by permission l. 
Figure 1.8 - Piggyback baboon to human liver xenotransplantation 
performed in June, 1992 (82), and January, 1993 (83l. The animal livers 
were approximately one quarter the ideal size for the adult male 
reCIpients. (From: Starzl TE, et al. Prospects of clinical 
xenotransplantation. Transplant Proc 1994;26(3):1082-1088. Used by 
permission). 
from a substantially smaller donor is to be used, beca~se it 
is easier to adjust disparities in length and size of the donor 
and recipient vessels as was necessary in our two recent 
baboon-to-human liver xenotransplantations (82, 83) 
(Figure 1.8), Also, smaller raw surfaces are created with the 
piggyback dissection, thus making subsequent hemostasis 
eaSIer. 
In small children in whom venovenous bypass may not 
be feasible, the combination of the piggyback technique 
and a temporary portacaval shunt (84) minimizes the 
physiologic disturbances of the anhepatic period. Finally, 
the fact that there are only 3 vascular anastomoses to do 
will always allow the donor liver to be reperfused 
simultaneously with portal and arterial blood_ Otherwise, 
the piggyback technique of liver implantation is similar to 
the standard one, except for the outflow anastomosis which 
is made to the anterior surface of the recipient vena cava, 
on a large common funnel fashioned by opening and 
interconnecting two or all three of the main suprahepatic 
veins. The lower end of the donor inferior vena cava IS 
either ligated or sutured (Figure 1.8), 
---------------_._--_ ...... -- .. " .... 
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Revascularization 
A number of anatomical problems that precluded liver 
transplantation up to the last decade are no longer absolute 
contraindications. When the recipient portal vein is 
thrombosed, or significantly smaller in diameter than the 
donor portal vein, the venous anastomosis can be 
performed at the confluence of the recipient splenic and 
superior mesenteric veins. If the donor portal vein is not 
long enough to reach this low. a free interposition graft, 
from donor iliac vein, can be used to bridge the gap (37, 
38). In cases where the portal thrombosis extends inferiorly, 
a venous graft can be "jumped" from the graft hilum to the 
host superior mesenteric vein (39, 40, 85). 
If a direct arterial reconstruction is not feasible, or when 
the arterial inflow is unsatisfactory, a so-called arterial 
conduit may be used (4,47.86-88), Many routes have been 
used in the past to bring a donor iliac graft from the 
recipient infrarenal aorta into the subhepatic area. 
Figure 1. C) - The route of free graft of donor iliac artery from the recipient 
aorta to the hilar area of an orthotopic liver graft. Nare the donor arterial 
anomalv in which the right. middle. and left hepatic arteries came 
separatelv from the aorta. The origin of these vessels was converted to a 
Carrel patch which was anastomosed to the end of the" conduit" graft. 
(From: Tzakis A. et al. The anterior route for arterial graft conduits in 
liver transplantation. Transplant Int 1989:2:121. Used by permission). 
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Currently, the preferred route is to pass the graft from the 
recipient aorta through an opening in the transverse 
mesocolon. behind the pylorus (Figure 1.9), The arterial 
graft can also be placed in parallel with a venous jump graft 
from the superior mesenteric vein. if both are required. The 
various vascular graft techniques described in this section 
enable today's liver transplant surgeons to accomplish a 
liver implantation with minimal hilar dissection. 
Biliary Tract Reconstruction 
In most of the first human cases, the homograft common 
bile duct was anastomosed to the recipient common duct 
over aT-tube stent (Figure 1.6, inset). Unfortunately, this 
approach was temporarily abandoned in favor of 
cholecystoduodenostomy, a technically easier operation 
that had worked well in canine experiments. The first 
inkling that unrecognized biliary obstruction was common 
came in a report by Martineau et al (89). Subsequently, the 
incidence of bile duct complications including obstruction. 
fistula and cholangitis was shown to be more than 30% (90-
92). Eventually, these problems were minimized by a return 
to choledochocholedochostomy with aT-tube stent or, if 
this was not feasible, choledochojejunostomy to a Roux 
limb (71, 91,92) (Figure 1.6). 
In England, Calne had encountered the same problems 
with biliary reconstruction (93), and he recommended a 
modification of the procedure developed by Waddell et al 
(94) at the University of Colorado. With the so-called 
Waddell-CaIne operation, the common duct of the 
homograft is anastomosed to the homograft gallbladder 
that then serves as an extension conduit to the recipient 
common duct or bowel. The Waddell-Calne operation is 
not used very often in most centers because of a high risk 
of stone formation (95), but it can be useful or even 
lifesaving in some complicated cases in which an extra 
length of the homograft common duct is needed. 
IMMUNOSUPPRESSION 
Earliest Efforts 
Total body irradiation (TBl) (96), adrenal cortical steroids 
(97, 98), and the myelotoxic drug 6-mercaptopurine (6-
MP) (99,100) were shown between 1953-1959 to modestlv 
prolong skin allograft survival in several animal specie;. 
Using TBI, successful kidney transplantation from fraternal 
(dizygotic) t\\'in donors was accomplished in patients at the 
Peter Bent Brigham Hospital (Boston) in January. 1959 and 
again 5 months later at the Hopital Necker (Paris). 
Although the genetic barrier to transplantation of the 
kidney finally had been breached in humans, liver 
transplant operations still had no conceivable application. 
Preoperative conditioning of hepatic canine recipients with 
------------------
L1\'ER TRAl\:SPLAl\:TATIO:\: FRO:-.t THE LABORATORY TO THE CLI:'\IC AND BEYO!'\D 13 
TBl appeared to preclude even perioperative, much less 
extended, survival (101). 
An historic turn in the road came in 1958 and 1959. when 
Schwartz and Dameshek described the immunosuppressive 
effect of 6-MP in non-transplant models (102, 103), 
Schwartz's intention from the outset was to use 6-MP in a 
different transplant strategy than previously. In September 
1959, he presented a paper at an international oncology 
meeting in London describing a dose-related prolongation 
of rat skin grafts. using non-myelotoxic doses of the new 
drug. His manuscript was submitted to the .Journal 0/ 
Clinical Investigation, but was delayed in publication until 
Tune 1960 (99), In the meanwhile, Robert Good's team at 
'the University of Minnesota had done similar skin allograft 
studies which were published rapidly in Proc Soc Exp Bio! 
Med in December 1959 (100) with acknowledgment of the 
Schwartz-Dameshek priority. Also aware of the Schwartzi 
Dameshek breakthrough, Roy CaIne did the first of his 6 
kidney transplants in dogs under 6-MP in late 1959 and 
early 1960. Two of his animals survived for 21 and 47 days 
(7). Independent similar observations also were recorded 
by Charles Zukoski, a young surgeon working with Dave 
Hume at the Medical College of Virginia (104). 
Zukoski, Lee, and Hume submitted their abstract to the 
Surgical Forum of the American College of Surgeons before 
the deadline of February 15, 1960, at the same time as 
Calne's results were reported in The Lancet. However, their 
manuscript was not published (Surgical Forum of the 
American College of Surgeons) until the first week of 
October, 1960 (104). The work of Schwartz and Dameshek, 
Meeker, CaIne and Zukoski was widely known in the 
United States and England by the spring and summer of 
1960. In fact, Rene Kuss in Paris already was using 6-
mercaptopurine for delayed therapy of his irradiated 
human kidney recipients as early as April, 1960 (105); in 
the same month, the drug was given to a human kidney 
transplant recipient at the Brigham (106). 
In July 1960, Calne moved to Boston, determined to 
press forward with preclinical trials of the purine analogues 
in collaboration with Joseph Murray. Because of the poor 
therapeutic margin of 6-mercaptopurine (and azathio-
prine), CaIne and Murray attempted to find drug 
combinations (8, 107, 108). Inexplicably, their experiments 
failed to show that the value of azathioprine was increased 
by combining it with adrenal cortical steroids (S, 106-lOS). 
Consequently, CaIne and Murray focused their intention 
instead on adjunct cytotoxic agents such as actinomycin C 
and a drug called azaserine. 
The preclinical kidney transplant studies in Boston and 
Richmond with 6-MP and its analogue, azathioprine, were 
viewed by us in a different light than anything previously 
done. Whereas kidney transplantation with long survival 
had never previously been possible in mongrel dogs, about 
5 % of animals given one or the other of the new drugs lived 
> 1 00 days after renal transplantation. Consequently, the 
objective of exploiting hepatic replacement to treat human 
liver disease was settled upon as a high priority during 
discussions in June. 1961. between one of us (TES) and 
William R. WaddelL who left the Massachusetts General 
Hospital to assume the chairmanship of surgery at the 
University of Colorado 5 months before TES moved from 
Chicago to Denver. The plan called for first establishing a 
track record in renal transplantation, a procedure under 
formal clinical development in the United States only in 
Boston and Richmond. 
Our clinical plans for both the kidney and liver were 
shelved in January, 1962. Until this time, we had been 
following the tracks laid by the American kidney transplant 
pioneers (Murray [with Calne] and David Hume) and 
those in Paris (Rene Kuss and Jean Hamburger), only to 
eventually realize that we had joined them in a therapeutic 
cui de sac. As late as March 1, 1963, the date of our first 
liver transplantation, only 6 recipients of kidney allografts 
in the world had survived ~ one year (one in Boston and 5 
in Paris), all treated with TBI. The clinical results with 
azathioprine-based immunosuppression were little better 
(106,109). Although the longest surviving kidney recipient 
treated by Murray solely with azathioprine or 6-MP-based 
therapy between April 1960 and April 1962 was now 11 
months postoperative, we knew from contact with Murray 
that the patient had deteriorating renal allograft function. 
The Colorado Drug Cocktail 
The experimental results with 6-MP and azathioprine in 
the Denver VA canine laboratory were no better than those 
in Boston and Richmond, with one notable exception 
(110). During the summer of 1962, high doses of 
prednisone were shown to reliably reverse kidney (and in 
pilot studies liver) rejection that usually developed under 
primary azathioprine therapy (111). Although most of the 
dogs died from complications of steroid-induced peptic 
ulceration, several lived for years after discontinuance of 
prednisone and even when azathioprine also was stopped. 
Using the "double drug cocktail", the Colorado clinical 
kidney transplant program finally was opened in 
November, 1962. 
The first 10 cases under azathioprine/prednisone im-
mune suppression were compiled rapidly and reported in 
the October, 1963, issue of Surgery, Gynecology, and 
Obstetrics (112), preceding by 2 months the article in the 
same journal describing the first trials of liver 
transplantation (77l. Four of the 10 renal recipients 
survived ~ 25 years including 2 who still bear the longest 
continuously functioning kidney allografts in the world 
after a third of a centurY (113), It alreadv was obvious that 
these patients could re[~rn to an unrest;icted environment 
on reduced maintenance immunosuppression, suggesting 
that a state of relative host/graft non-reactivity had been 
accidentally but regularly induced bv the renal allografts. 
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The controversial. but as it turned out apposite. term 
"tolerance" (see later) was used to describe the change 
(112). 
THE FIRST CLINICAL LIVER TIliALS 
The breakthrough with the "Colorado cocktail". and its 
successful application for kidney recipients was the signal 
that triggered the liver trials. The first 3 patients entered 
were: a moribund child with biliary atresia. a 48-year-old 
man with Laennec's cirrhosis and an unresectable 
hepatoma, and a 62-year-old man with a completely 
obstructing bile duct carcinoma who had previously 
undergone bilateral above-knee amputations for peripheral 
vascular disease. Their high risk factors would preclude 
candidacy today. Although 2 survived the operation, 
neither left the hospital alive. The redacted summary of the 
report of these trials (77) is given below. 
"A number of problems are described which must be 
surmounted for the clinical use of liver homotran-
splantation, based upon experience with 3 patients. The 
first patient died of hemorrhage during conclusion of the 
operation. The second and third patients lived for 22 and 
7-1/2 days, respectively, both ultimately dying from 
multiple pulmonary emboli ... Procurement of a viable 
and relatively undamaged donor organ [was] . . . 
accomplished with the use of an extra corporeal circuit 
which perfuses and cools the [donor] liver immediately 
after death ... It has been found necessary to decompress 
only the inferior vena cava during [the anhepatic] time 
with an external bypass from the inferior to the superior 
vena caval systems . . . During operation, a bleeding 
diathesis was regularly detectable . . . The use of the 
external bypass and [delayed] hypercoagulability may 
have contributed to the formation of the [pulmonary] 
emboli ... Hepatic functions were immediately deranged 
[postoperatively], probably as the result of injury incurred 
during the transplantation, with progressive improvement 
thereafter ... Biochemical evidence of [irreversible] 
homograft rejection was not observed, and at autopsy in 
the last 2 patients there was surprisingly good gross and 
histologic preservation of graft structure ... Therapy with 
azathioprine, prednisone, and actinomycin Chad 
forestalled the rejection process." 
Most failed trials are doomed to be footnotes, if that 
much, in the pages of history. The 1963 liver transplant 
article escaped obscurity because it was based on principles 
that were enduring. Aside from the manifold details of the 
difficult operation, including the role of and complications 
from veno-venous bypass, there already was accurate 
insight into the importance of hepatotrophic physiology, 
and into the cause and treatment of metabolic acidosis. The 
only non·surgeon author. Kurt von Kaulla. anticipated the 
intraoperative coagulation disorders, monitored them with 
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serial thromboelastograms. and provided treatment with 
blood components and epsilon amino caproic acid (an 
analogue of the currently used aprotininel. Lessons from 
the research preceding the clinical trial already had cross-
fertilized to the kidney and eventually were exploited for 
all kinds of allografts: core cooling by infusion of chilled 
intravascular fluids. in situ procurement procedures that 
presaged the standard flexible procedures of today (58, 65), 
and the intravascular techniques required for close-quarter 
anastomoses. 
The Liver Moratorium 
The Colorado kidney center mushroomed overnight while 
the spark that had ignited it, liver transplantation, was 
consigned by the end of 1963 to a self-imposed 3-112 year 
worldwide moratorium following 4 more failures: 2 in 
Denver (9) and one each in Boston (114) and Paris (l151. 
Three advances applicable to all organs were made during 
this period: 1) the purification and clinical introduction in 
1966 of antilymphocyte globulin (ALG) for use with 
azathioprine and prednisone in a triple drug regimen (l16); 
2) preservation techniques that allowed livers to be stored 
ex vivo for one to 2 days (69); and 3) the demonstration 
(with Paul Terasaki of UCLA) that the quality of 
donor/recipient HLA matching had little association with 
kidney transplant outcome (117). It was assumed 
(correctly) that the same non-discrimination of tissue 
matching would apply with other organs. 
Clinical Success (1967) 
When the liver program was reopened in July, 1967, during 
the 2-year fellowship of Carl Groth (Stockholm), multiple 
examples of prolonged liver recipient survival were 
. produced (4, 118). A second liver transplant program was 
founded in 1968 by Roy Calne of Cambridge University 
(79) and fostered by a long lasting inter-university 
collaboration with the hepatologist Roger Williams at 
King's College Hospital, London. The American and 
English teams sustained each other for the next dozen 
years, joined in the early 19705 by Rudolph Pichlmayr in 
Hannover and by Henri Bismuth in Paris, always 
tantalizingly close to making liver transplantation a service. 
In Denver. 170 patients underwent the operation between 
1963 and 1979. Although only 56 survived for 1 vear, 25 
were alive after 13 to 22 years at the end of 1992 (1 i 9), and 
19 remain today with follow-ups of 17 to 27 years. 
Cyclosporine and Tacrolimus 
Although the feasibility of liver transplantation was 
established. the results remained unacceptable until Sir Roy 
Caine. who had presided over the preclinical development 
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of the thiopurine drugs in Boston nearly 2 decades before, 
repeated the feat with cyclosporine and then reported the 
first clinical series which included 2 liver recipients {1201. 
In another visit to the past, the full potential of the new 
drug was realized for transplantation of the kidney (121), 
liver (122), and eventually all organs when it was combined 
with prednisone or used in triple drug cocktails, The 
stampede to develop extrarenal transplant centers began, 
Nine years later, expectations moved up another notch with 
the advent of tacrolimus (123, 124) (Figure 1.10). 
It is noteworthy that intensive efforts over a span of 35 
years to develop better immune suppression have resulted 
in only a handful of widely used regimens (Table 2). These 
were based on azathioprine (or cyclophosphamide), 
cyclosporine, and tacrolimus with or without antilymphoid 
agents (polyclonal ALG and monoclonal refinements) or 
myelosuppressive adjuncts. The one indispensable second 
drug was prednisone. 
TABLE 2 
IMMUNOSUPPRESSIVE DRUGS IN ORGAN 
TRANSPLANTATION 
Agents Year Reported Institution (Ref) 
Azathioprine 1962 (106) Peter Bent Brigham Hospital 
Azathioprine·steroids 1963 (112) University of Colorado 
Cyclosporine 1979 (120) Cambridge University 
Cyclosporine-steroids 1980 (121) University of Colorado 
Tacrolimus-steroids 1989 (23) University of Pittsburgh 
CHIMERISM AND THE TWO-WAY PARADIGM 
As it turned out, none of the individual drugs. or all 
together, remotely approached in importance the reali-
zation in the summer of 1962 that rejection could be 
engineered into prolonged allograft and recipient survival 
by the strategic use of multiple agents, always including 
adrenal cortical steroids (112). The cyclic pattern of 
convalescence and the consequent achievement of allograft 
acceptance remained enigmatic until it was discovered in 
1992 that long-surviving organ recipients had donor 
leukocyte chimerism (119. 125), 
The Phenomenology 
This link between bone marrow and organ transplantation 
was provided when micro chimerism was detected with 
sensitive immunocytochemical and polymerase chain 
reaction (PCR) techniques in the tissues or blood of all 30 
human kidney or liver recipients studied from 2.5 to 30 
years postoperatively (119, 125). The donor cells were 
multilineage, but paradoxically many appeared to be 
dendritic cells (DC), a potent antigen presenting cell (APC) 
(126). Individual samples from patients often do not 
contain the donor leukocytes, which wax and wane (127). 
However, disseminated donor cells, including DC, and/or 
donor DNA are consistently demonstrable if rodents 
bearing long-term grafts are completely studied 028-131). 
Along with peripheral migration of the donor cells from 
a successfully transplanted graft, there is an influx of host 
leukocytes which do not cause graft damage (Figure 1.11A) 
(119). Thus, both the allograft and recipient become 
genetic composites, A mirror image condition exists after 
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F,gure 1.10 - The 3 eras of orthotopic liver 
transplantation at the Universities of Colorado 
( 1963 ·80) and Pittsburgh (1981·19931. defined bv 
immune suppression based on azathioprin~I 
cyclosporine, and FK 506 (tacrolimusl. Graft 
survival (shown here) was about 10'/'0 lower than 
patiem survival in the cyclosporine (1980-89\ and 
tacrolimus eras (1989·93) because of retranspla-
mation. an option that did not exist previously 
(data from 124). 
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A. Two-Way Paradigm (Organ) 
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Figure 1.11 - Two·way paradigm with which transplantation is seen as a 
bidirectional and mutually cancelling immune reaction that is (A) 
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GVH with bone marrow grafts. 
c 
.2 
(3 
., .• -._, 
.' ., 
./ HVG "'" Recipient 
.' .... 
.' .... 
LIVER TRANSPLANTATION 
bone marrow transplantation (132) (Figure l.I1E), proved 
by demonstrating a trace residual population of host 
leukocytes in essentiallv all stable human bone marrow 
recipie~ts who previou~ly were thought to have complete 
donor-cell chimerism (133), 
Previous Enigmas 
Graft Acceptance - These discoveries have provided an 
important framework for a better understanding of 
allograft "acceptance" , for analysis of management 
problems, and for therapeutically oriented transplantation 
research (134). In the new context (the 2-way paradigm), 
the donor leukocytes in organ recipients constitute the 
small member of antagonistic but reciprocally attenuated 
or abrogated host·versus.graft (HVG) and graft-versus-
host (GVH) arms. each of which can induce specific non-
reactivity (tolerance) in the other (119, 125, 132, 134) 
(Figure 1.12). Deletion of the host arm by cytoablation 
prior to bone marrow but not organ transplant alters the 
balance in this mutual interaction and is thus responsible 
for the disparities in the two different kinds of 
transplantation (Table 3). 
The 2-way paradigm defines success and failure after 
transplantation in a different way than before. Success 
implies that chimerism has been introduced which mayor 
may not be immunosuppression-dependent. Failure 
connotes the therapeutically uncontrollable ascendancy of 
HVG or GVH. Pathologic evidence of both processes 
frequently is found in failed liver or intestinal transplant 
cases, but the ultimate result is predominantly rejection or 
GVHD, In kidney recipients who are exposed to a small 
load of passenger leukocytes, pathologic findings in the 
recipient and allograft are usually those of rejection only. 
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FIgure 1. 12 - Contemporaneous host versus graft 
(HVG, and graft versus host (GVH, reactions in 
the two·way paradigm of transplantation im· 
munology. Following the initial interaction. the 
evolution of non· reactivity of each leukocyte 
population to the other is seen as a predominantly 
low-grade stimulatory state that may wax and 
wane. rather than a deletional one. 
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TABLE 3 
DIFFERENCES BETWEEN CONVENTIONAL 
BONE MARROW AND ORGAN TRANSPLANTATION 
BOlle Marrow Orgall 
Yes ~ Recipient Cytoablation" ~ No 
Critical ~ MHC Compatibility ~ Not Critical 
GVHD ~ Principal Complication ~ Rejection 
Common ~ Drug Free State ~ Rare 
Tolerance ~ Term for Success ~ " Acceptance"*" 
" Note: All differences derive from this therapeutic step which in effect 
establishes an unopposed GVH reaction in the bone marrow recipient whose 
countervailing immune reaction is eliminated. 
*" Or "operational tolerance" 
After liver transplantation. however, stigmata of GVHD are 
not rare (19). 
Other Enigmas - The dynamic 'nullification' effect of the 
two arms makes it obvious why organ recipients can 
sometimes stop immunosuppression without losing their 
allografts (34). It also explains the poor prognostic value 
of HLA matching for organ transplantation; the rarity of 
GVHD following the engraftment of immunologically 
active organs such as the intestine and liver. 
The Counter-Argument 
In the previous conception of organ allograft acceptance, 
which excluded a role for lymphoid cell microchimerism, 
it was axiomatic that antigens of the parenchymal (or 
vascular endothelial) cells of transplanted organs permitted 
or induced allograft acceptance (135) in various ways e.g. 
via veto/suppressor cells, cytokine profile changes or 
enhancing antibodies. In an extension of such reasoning, it 
has been contended that the microchimerism associated 
with successful organ transplantation, and conversely its 
disappearance with or just after irreversible rejection in 
experimental models (128, 130), is epiphenomenal (136) 
and inconsistent. 
Such arguments have been skillfully summarized in a 
debate format by Wood and Sachs (137). However, there 
is no credible evidence to support their contention that the 
microchimerism found in organ recipients is the effect, 
rather than the cause of allograft acceptance. Failure with 
limited tissue or blood sampling to find peripheral 
microchimerism in patients after successful organ 
transplantation (127) connotes an incomplete search. In 
our clinical studies in which sampling was from multiple 
sites, the yields from individual locations were comparable 
to those of other investigators. However, when the results 
were pooled from the different sites in individual cases, all 
30 of our originally tested patients had microchimerism 
(119), In rat experiments where tissues can be retrieved 
without limit. the association of chimerism with avoidance 
of chronic rejection has been absolute in our hands (l31l. 
Post-Transplant Lympboproliferative Disorders (PTLD) 
The 2-way paradigm has shed light on the pathogenesis of 
PTLDs (138), Except for their frequent Epstein-Barr virus 
mBV) association, these human B-cell lymphomas are 
indistinguishable from those induced by Robert S. 
Schwartz in a mouse chimerism model (39) 3 years before 
the PTLD complication was first recognized clinically (140) 
and explained by simple loss of surveillance (41). Rather 
than simple loss of surveillance, Schwartz (the same man 
who introduced 6-MP and azathioprine, see earlier) 
ascribed the tumors to an active lymphoproliferative 
response by the dominant immune apparatus to the 
persistent subclinical GVH counterattack of the minority 
donor leukocyte population. The relevance of his 
observations to clinical PTLD could only be appreciated 
30 years later with the discoveries of microchimerism. 
Then, it could be seen that PTLD is a complication of 
the joint activation of the coexisting immune populations, 
to which powerful co-factors are added that act upon both 
(138). Because host leukocytes in most organ recipients 
vastly outnumber the chimeric donor cells, with a similar 
obverse disproportion in successfully engrafted bone 
marrow recipients, clinical PTLD are usually of recipient 
origin in the first instance (142-144), and of donor 
phenotype in the second (143, 145, 146). There are 
exceptions to this generalization, but not to the principle. 
For example, if the minority immunocyte population of 
an organ recipient unexpectedly gains ascendancy, the 
recipient is at primary risk of GVHD, but there is a 
corollary hazard of donor type PTLD. Conversely, the 
presence of a large recipient cell population in a bone 
marrow recipient with mixed chimerism implies a 
proportionate risk of a host PTLD. The exceptional PTLD 
of donor phenotype in organ recipients usually are seen 
during the early post-transplant period of mutual co-option 
of the 2 immune systems. 
In the Schwartz model, heightened leukocyte cell renewal 
was ascribed solely to smoldering GVH. In human PTLD, 
however, this and all other B cell-stimulating influences 
would seemingly be dwarfed in importance by the presence 
ofEBV with its uniquely potent B cell-transforming quality 
(47). However, the pathogenetic factors in the Schwartz 
model and the EBV infected transplant recipient are not 
mutually exclusive. It requires no imagination to postulate 
that their combination would send already heightened B 
cell proliferation into overdrive. 
Also different from the Schwartz model, heavy immuno-
suppression typically precedes the appearance of the 
tumors in the human organ recipient. Conversely, reduction 
or discontinuance of the anti-rejection drugs (148) can 
allow restoration of immune surveillance, manifested by 
PTLD regression. Tumor involution frequently is 
coincident with organ rejection, but in most cases a level of 
immune suppression can be reachc:d by trial and error that 
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permits salvage of the allograft without precipitating re-
growth of the lymphoma 048-1501. 
The way in which this fresh insight can be used to map 
strategies of PTLD treatment is discussed elsewhere (38). 
The point here is that PTLD syndromes are aberrations, 
heavily influenced by co-factors, of the same interactions 
between donor and recipient cell populations by which 
allograft acceptance is achieved (119, 125, 132, 134). 
Immune suppression is a dominant co-factor, particularly 
when it is T cell-directed. Consequently, it was not 
surprising to note an incremental increase in PTLD with 
successively more potent immunosuppressants. However, 
the risk of PTLD can be reduced at the outset by avoiding 
the joint use of the biologic antilymphoid agents (i.e. ALG 
and OKT3) with cyclosporine and tacrolimus except as a 
last resort, and then with extreme caution. When PTLD is 
diagnosed early in development, it usually is a trivial 
problem requiring only drug dose reduction. 
THE FUTURE OF TRANSPLANTATION 
Tolerance Induction 
In the context of the 2-way paradigm, historic efforts to 
improve transplantation results with donor-specific blood 
transfusion (l5I) and the donor bone marrow 
augmentation of organ recipients (152, 153) were based on 
sound therapeutic principles involving the unrecognized 
augmentation of chimerism. It is also obvious why whole 
organs are inherently tolerogenic. Their engraftment 
involves a small coincidental extramedullary bone marrow 
transplantation, including pluripotent stem-cells (I54). 
Understanding the concept of the subsequent 
donor/recipient leukocyte dialogue helps predetermine 
what can {and cannot} be accomplished with various 
tolerance-inducing strategies, all of which are attempts to 
influence this interaction. Our first clinical premise was 
that the spontaneous microchimerism of organ 
transplantation could be greatly augmented by the co-
administration of unmodified donor bone marrow cells 
without a significant risk of GVHD, providing the two 
immunocyte populations were initially competent and that 
immunosuppression was delivered to both equally. It also 
was predicted that the timing, severity, and frequency of 
acute rejection would be approximately the same as in non-
marrow augmented control patients 025, 155, 156). 
These expectations have been fulfilled in 200 human 
organ recipients treated at the University of Pittsburgh 
(156-158), including 86 who were given kidneys. The 
presence of donor DNA in the mveloid and erYthroid 
colonies generated from recipients P'BMC as meas~red in 
standard (157) or innovative clonal hematopoietic 
progenitor cell assays (159) has provided unequivocal 
LIVER TRANSPLANTATION 
evidence of augmented stem cell chimerism. There were no 
examples of significant GVHD. 
The hypotheses of therapeutic efficacy being tested are 
that the threat of delayed (acute or chronic) rejection can 
be reduced and that the frequency of ultimate drug 
independence can be increased by the higher persistent 
level of chimerism. An efficacy evaluation is expected to 
take 5 to 10 years (134, 155), roughly the same time frame 
for tolerance induction learned from clinical experience 
with MHC-incompatible liver and bone marrow 
transplantation. 
Other chimerism-enhancing strategies (e.g. G-CSF, GM-
CSF or the new hematolymphopoietic growth factor, 
glycosulated FIt-3 ligand [160]) should follow the same 
safety/efficacy rules. In contrast, procedures that alter only 
one of the interacting arms must be approached with 
caution, as exemplified by the historical experience with 
GVHD following cytoablation and bone marrow 
transplantation. When the converse tactic of leukocyte or 
T-cell specific depletion of intestinal allografts was 
attempted as GVHD-prophylaxis in the 1980s, virtually 
every bowel recipient who survived the perioperative 
period developed lethal Epstein-Barr virus-associated B-
cell lymphomas (53). 
Unbalance also can be caused by delayed provision of 
donor leukocytes (e.g. repeat infusion of adjunct donor 
bone marrow to an organ recipienr). To the extent that the 
first exposure (whether to infused leukocytes or to 
passenger leukocytes in a transplanted organ) induces 
tolerance, the result of the second stage delivery can 
resemble the effect of a parent to defenseless offspring F 1 
hybrid experiment (128). Investigators signing on for 
multicenter trials of serial bone marrow augmentation 
should be made aware of this serious and predictable risk 
ofGVHD. 
Xenotransplantation 
Further growth or transplantation will depend on the use 
of animal organs. This inevitably must conform to the 
guidelines painfully acquired over 35 years with allo-
transplantation. The creation of transgenic animals is in 
essence an attempt to improve the cross species tissue 
match, and is specifically designed to eliminate the barrier 
of hyperacute humoral rejection by transfecting human 
complement regulatory genes (161-163), This has been 
accomplished in pigs, but it will not remove the necessity 
of maintaining cohabitation of the animal and human 
immune systems, as defined by the 2-way paradigm. 
The possibility of achieving the latter objective has been 
demonstrated by Zanjani et al 064, 165), who inoculated 
sheep embryos intraperitoneally at the 40 to 50 day stage 
of the 120 day gestational period with leukocytes from 
human fetal livers, or with human stem cells purified from 
adult bone marrow. A handful of the sheep fetuses 
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completed their intrauterine life in a healthy state and have 
stable with> 5 % human leukocyte chimerism 6 to 7 years 
later (165). 
We have shown that stable chimerism also can be 
~1Ccomplished in piglets given unaltered adult bone marrow 
mtravenously a few hours after birth, without any 
Immunosuppression. One year after birth, there was 
evidence of donor-specific as well as species hyporeactivity 
in the healthy chimeric animals (166). At 14 months, the 
chimeric cells could be dramatically upregulated with 
injections of human GM-CSF (unpublished observations, 
University of Pittsburgh). 
Because the primary source of complement is the liver, 
not the hematolymphopoietic system, it is unlikely that 
humoral rejection caused by the interspecies complement 
activation will be abrogated, no matter what the duration 
of chimerism (66). However, by inducing chimerism in 
pigs who already have human complement regulatory 
proteins in their organs at birth, the barrier of complement 
activation and cellular tolerance may be jointly approached. 
Such experiments are underway at the University of 
Pittsburgh. 
CONCLUSION 
The specialty of organ transplantation was an anomaly 
which acquired shape and substance by trial and error 
rather than springing from a well formulated scientific base 
or from a theoretical model. Its supporting stntts are 
prevention of rejection, tissue matching, organ preserva-
tion. and surgical technique. However, only the last of these 
conformed to expectations. Consequently, the steps leading 
to practical clinical application of transplantation were 
empirical, each higher level of success appearing to violate 
more egregiously biologic (including genetic) rules that had 
been viewed as immutable. The consequence was a 
succession of unexpected small and great discoveries in the 
laboratory and in the clinic about how the immune system 
actually worked in the whole animal or human. Because of 
its complex structure and function, the liver, above all 
organs, was the supreme instrument of scientific 
exploration because it also served as the ultimate metabolic 
and physiologic probe. 
The inability to explain why transplantation succeeded at 
all with any organ, much less routinely, made the evolution 
of this field the most enigmatic in the history of medicine. 
The assumption that stem cell-driven hematolympho-
poietic chimerism was irrelevant to successful whole organ 
transplantation as currently practiced led to alternative 
inadequate explanations of organ allograft acceptance. 
clouded the meaning of successful bone marrow transpla-
ntation. and precluded for more than three decades the 
elucidation of a cardinal principle of transplantation. The 
recent recognition of this error and the incorporation of the 
chimerism factor into a two-way paradigm has allowed 
previous mysteries of organ as well as bone marrow 
engraftment to be explained and should allow the genius 
of basic science to be more meaningfully exploited in 
transplantation, including across species barriers. Thus. far 
from nearing its end. the history of transplantation and its 
role in medicine has only just begun. 
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